Other languages Cabaletta Bio, Inc.

Equities

CABA

US12674W1099

Market Closed - Nasdaq Other stock markets 16:00:02 2024-05-16 EDT			5-day change	1st Jan Change
12.62 ^USD	-0.59%		+3.23%	-44.43%

05-15	Cabaletta Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
03-22	HC Wainwright Adjusts Cabaletta Bio's Price Target to $30 From $25, Maintains Buy Rating	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Cabaletta Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-15
Cabaletta Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-21
Cabaletta Bio, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-21
Cabaletta Bio Gets Orphan Drug Designation From FDA For Systemic Sclerosis Treatment	03-20
Cabaletta Bio Secures Orphan Drug Designation for Myositis Treatment	02-02
Cabaletta, Inc. Announces FDA Grants Orphan Drug Designation to CABA-201	02-01
Cabaletta Bio Gets Additional FDA Fast Track Labels For CABA-201	01-08
Cabaletta Bio, Inc. Receives Additional FDA Fast Track Designations for CABA-201 in Dermatomyositis and Systemic Sclerosis	01-08
Sector Update: Health Care Stocks Retreat in Late Afternoon	11-28
Sector Update: Health Care	11-28
FDA Probes T-Cell Malignancies in Patients Receiving CAR-T Cell Therapies	11-28
Cabaletta Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09
Cabaletta Bio Says US FDA Cleared Generalized Myasthenia Gravis Phase 1/2 Study of CABA-201	11-06
Cellares and Cabaletta Bio, Inc. Partner to Evaluate Automated Manufacturing for CABA-201	11-06
Cabaletta Bio, Inc. Receives FDA Clearance of CABA-201 IND Application for Treatment of Generalized Myasthenia Gravis	11-06
Cabaletta Bio Insider Sold Shares Worth $146,921, According to a Recent SEC Filing	23-10-20
Cabaletta Bio Gets FDA Clearance For Trial in Systemic Sclerosis	23-10-02
Cabaletta Bio, Inc. Receives U.S. Food and Drug Administration Clearance of Investigational New Drug Application for Treatment of Systemic Sclerosis with CABA-201	23-10-02
Top Midday Gainers	23-09-18
Insider Sell: Cabaletta Bio	23-08-22

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Cabaletta Bio, Inc.

Equities

CABA

US12674W1099

Other languages

Filters